It may be possible to define pregnancy complication risk in the first trimester by combining biochemical and biophysical markers with obstetric history. This could allow antenatal care to be personalised, with patient and complication-specific content. Molecular genetic testing, by both invasive and noninvasive means, can offer examination of the whole genome or exome. Noninvasive prenatal testing (NIPT) using cell-free fetal DNA in the maternal circulation can offer screening and diagnosis of aneuploidy and single gene defects. Ultrasound can be enhanced by magnetic resonance imaging to provide imaging that is not limited by fetal and maternal characteristics, and can be used to assist preoperative planning for fetal surgery.
Introduction
Prenatal diagnosis has traditionally relied on two main modalities to identify abnormalities of fetal development: ultrasound scanning and invasive testing to obtain fetal cells or fluids.
Ultrasound scanning has been utilised principally for diagnosing fetal structural anomalies since 1956. However, with advances in both ultrasound and its supporting computer technology, 'real-time' 2D and 3D imaging has developed. Ultrasound provided a modality that could be used to screen the fetus for markers associated with genetic disease, such as aneuploidy. Initially, these markers were identified at the second trimester ultrasound scan with variable sensitivity and specificity; therefore, screening for aneuploidy, specifically trisomy 21 (Down syndrome), focused on maternal serum tests.
In the late 1980s, serum markers, originally used for screening for neural tube defects and anencephaly, were applied to 'second trimester serum screening' involving the 'double test' (measuring analytes of alphafetoprotein and total human chorionic gonadotrophin [hCG] ). Their sensitivity and specificity were subsequently improved by the addition of other analytes, initially serum estriol (the 'triple test') and then inhibin (the 'quadruple test'), with improved detection rates.
The extensive work from Kypros Nicolaides' group at King's College Hospital showed an association between increased measurement of first trimester nuchal translucency (NT) and Down syndrome, making NT measurement a potential screening test. Large prospective studies [1] [2] [3] have demonstrated an improvement in detection rate for trisomy 21 from 77% for NT alone (false positive rate of 4.7%) 4 to 85-90% for a combined first trimester test using measurement of NT and placental protein markers free b-hCG and pregnancy-associated plasma protein A (PAPP-A) (false positive rate of approximately 5%). 1, 5 The Health Technology Assessment of Antenatal Screening for Down's Syndrome, 1 published in 2003, showed that an integrated test using first and second trimester measurements offered the best overall performance (false positive rate of 1.2% for detection rate of 85%); however, to allow women the choice of a first trimester test, it recommended the combined test.
Integrated first trimester assessment
The common theme throughout the development of both biochemical and ultrasound screening has been that initially tests were conducted in the second trimester but refinement then made first trimester screening possible. The notion of early prediction of pregnancy complications has promoted interest in redefining the way we provide overall prenatal care. 6 Nicolaides describes how the current obstetric care model focuses on the late third trimester in terms of concentration of antenatal visits, implying that most complications occur at this time and are unpredictable. 6 By contrast, he has suggested an inverted model of care based on an integrated first trimester assessment, that considers maternal characteristics and obstetric history with ultrasound and biochemical testing of maternal blood. 6 This, he postulates, could stratify women into low-or highrisk groups, with the majority of women designated low risk as currently holds true. Thus, this majority of pregnancies could follow a much reduced schedule of antenatal care comprised of first trimester assessment, a midtrimester scan and then maternal and fetal wellbeing checks at 37 and 41 weeks of gestation. 6 Those women identified as high risk would embark on specialised care between 12 and 34 weeks of gestation to try to predict and manage potential complications.
In this new pyramid of care model, it is proposed that the risk of complications such as miscarriage, preterm delivery, pre-eclampsia and fetal growth restriction can be ascertained. 6 All patients would be offered aneuploidy screening, and this would comprise maternal serum free b-hCG and PAPP-A at 9-10 weeks and then fetal NT at 12 weeks as, for example, a low PAPP-A is associated with an increased risk of miscarriage and stillbirth. 6 This would enable classification of pregnancies into high, intermediate or low risk, with those intermediate in risk going on to be reclassified as high or low risk after a second ultrasound scan that includes assessment of the nasal bone, as well as blood flow in the hepatic artery, ductus venosus and across the tricuspid valve. 6 In addition, those women identified from history and maternal characteristics as being at high risk of preterm birth would also have first trimester measurement of cervical length; likewise, a uterine artery Doppler and mean arterial blood pressure would be used to check for risk of impaired placentation as relevant to prediction of both preeclampsia and fetal growth restriction. Other possibilities include measurement of placental growth factor, because low levels have been linked to the risk of pre-eclampsia, and measurement of sex hormone-binding globulin and adiponectin levels, as these may be associated with the risk of gestational diabetes. 6 All these tests would be viewed in combination with maternal characteristics and obstetric history, and in this way subsequent antenatal care could be individualised, with patient and complicationspecific content. 6 In the situation where an anomaly was detected, appropriate follow-up in terms of further imaging (that is, detailed ultrasound with or without magnetic resonance imaging [MRI] ) and/or fetal karyotyping could be considered as appropriate. However, despite advances in the predictive index of scanning, ultrasound scanning can still only provide screening for chromosomal anomalies, such as aneuploidy, translocations, duplications or deletion and inversions.
Invasive testing
Traditionally, invasive testing to obtain fetal cells, in the form of percutaneous, ultrasound-directed needle insertion into the amniotic cavity, placenta or, less commonly, the fetal circulation would allow a chromosomal anomaly to be excluded (or the diagnosis confirmed). However, such invasiveness is unpleasant for the patient and carries a risk of miscarriage.
These invasive tests, most commonly chorionic villus testing (CVS) between 11 and 14 weeks of gestation and amniocentesis from 15 weeks, were considered the only way to examine fetal cells and ultimately the chromosomal complement of the fetus. Karyotyping, where the number and microscopic appearance of the chromosomes could be ascertained, was traditionally used but testing has subsequently developed to include both more targeted analysis, such as fluorescence in situ hybridisation (FISH), and more detailed analysis through the use of chromosomal microarray (CMA), also known as array comparative genomic hybridisation (aCGH). This molecular cytogenic technology has an advantage over karyotyping in that it can obtain a greater level of detail regarding chromosome aberrations; the highest resolution for conventional karyotyping by Giesma banding is 3 Mb, 7 but for FISH this is 1-2 Mb 8 and 1 kb 9 for aCGH. For this reason, aCGH has been shown to be as good as conventional karyotyping at identifying aneuploidy and unbalanced chromosome rearrangements, although it does not identify truly balanced translocations, low-level mosaicism or triploidy. However, the latter problem can be overcome by analysing much smaller DNA changes that affect only one nucleotide base, known as single nucleotide polymorphisms (SNPs) (so called SNP-based CMA). 10 CMA can also find copy number variants (alterations to large regions of the DNA of a genome) of which the significance is not known, termed variations of unknown significance.
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CMA can facilitate the diagnosis of clinically relevant deletions or duplications in 3-6% of fetuses with an apparently normal karyotype, particularly those with a structural abnormality, 9, 11 and is already widely accepted and used worldwide in the prenatal setting.
Next generation sequencing (NGS)
The use of NGS, a group of high-throughput DNA sequencing technologies, has enabled the interogation of the genome to the gene level. In this setting, exome sequencing (focused evaluation of the coding regions of the genome) is often favoured as this 1-2% of the genome is where 85% of gene anomalies reside. 10 Invasive testing for fetal anomaly using exome sequencing of DNA trios (that is, an affected fetus [proband] with both parents) has the ability to provide additional diagnostic genomic information in up to 10% of cases, which is supplementary to that of existing microarray testing. 12 Such technology is being evaluated by the Wellcome Trust Health Innovation Challenge Fund Prenatal Assessement of Genomes and Exomes (PAGE) study, which aims to recruit 1000 probands (as trios) with a prenatal diagnosis of fetal anomaly. 10 
Noninvasive prenatal testing (NIPT)
Despite the level of detail aCGH can provide, it still requires an invasive test to provide the fetal DNA for study. Since 1997, when Dennis Lo was successful in detecting fetal DNA in maternal plasma, focus has been on the possibility of collecting fetal cells by noninvasive methods. Transcervical sampling to detect the presence of trophoblast cells was reported in the 1990s 13 and offered the potential for molecular prenatal diagnosis. However, isolation of cell-free fetal DNA from the maternal circulation has received greater interest. This discovery came after decades of work, which focused initially on circulating DNA in the plasma after it was shown in 1948 that extracellular DNA and RNA was present in both healthy and sick individuals.
14 Subsequent work was undertaken, particularly looking at those with autoimmune disease and cancer, and it was shown that tumour cells can release their DNA into the circulation. 15 This prompted researchers to look for other forms of non-host DNA in the plasma or serum, and the first report of cell-free fetal DNA isolated from the maternal circulation was in 1997. 16 Furthermore, in 1998 it was confirmed that this is present from as early as 6-7 weeks of gestation and in early pregnancy constitutes approximately 3.4% of the total plasma DNA, rising to 6.2% in late pregnancy. 17 Similarly, fetal mRNA is also present in the maternal circulation at an early stage, 18 and it is accepted that the placenta is the predominant source of fetal nucleic acid and, therefore, the possibility of using these markers in NIPT gained momentum.
It is widely accepted that the placenta is the predominant source of fetal nucleic acid 19 in the maternal plasma but that fetal nucleic acid only accounts for a minority of the cell-free nucleic acid present. 20 For this reason, the method used to detect this subpopulation of cell-free nucleic acid must be able to differentiate this from the background maternal nucleic acid. 20 Initial success with NIPT has therefore focused on diagnosis of paternally inherited traits for which the mother and fetus were discordant, including Rhesus (Rh) status and fetal gender determination.
Rhesus (Rh) status determination
Noninvasive prenatal fetal Rh status determination has dramatically altered the management of pregnancies in women who are Rh D negative. Comprehensive polymerase chain reaction (PCR) Rh D genotyping tests have been developed and led to the introduction of routine NIPT for fetal Rh status for all Rh-negative women in Denmark. 21 Prenatal determination of the Rh status of the fetus can avoid the need for anti-D administration if the fetus is also confirmed to be Rh D negative. However, an economic evaluation performed in 2011 concluded that this strategy was not a cost-effective solution in England and Wales, 22 although NIPT is highly beneficial in the management of pregnancies in women affected by Rh isoimmunisation due to prior exposure to the Rh D antigen.
Fetal sex determination
Noninvasive detection of fetal gender also employs PCR, or preferably real-time quantitative PCR, for the detection of DNA sequences from the Y chromosome in maternal plasma and in a 2011 systematic review was shown to have a high sensitivity (95.4%) and specificity (98.6%). 23 The sensitivity and specificity were greatest if performed after 20 weeks of gestation; however, as long as the test was performed after 7 weeks it maintained sensitivity and specificity of 95% or greater. 23 This advancement is of great significance for pregnancies at risk of X-linked conditions, such as haemophilia, and can avoid the need for invasive testing. Likewise, it is useful in the management of pregnancies at risk of congenital adrenal hyperplasia, 24 where the side effects of maternal administration of steroids (to prevent virilisation of a female fetus) can be avoided where the fetus is confirmed to be male. Similarly, immediate neonatal management in cases where ultrasound has suggested ambiguous genitalia can be improved by NIPT of fetal gender. 25 However, the availability of noninvasive fetal gender determination raises the possibility of its use for fetal sex selection and therefore the issue of the ethical basis for offering this test for anything other than medical indications.
Reliable Accurate Prenatal non-Invasive Diagnosis (RAPID) study
In the UK, the 2009 RAPID study was funded to improve the quality of National Health Service (NHS) prenatal diagnostic services. 26 One aim of this study was to confirm laboratory standards for NIPT for fetal sex determination, ª 2016 Royal College of Obstetricians and Gynaecologists and to expand this to single gene disorders. 26 RAPID has shown the ability to detect or exclude paternal inherited or de novo mutations for autosomal dominant conditions, such as skeletal dysplasias (Thanatophoric dysplasia, achondroplasia, Apert and Crouzon syndromes), torsion dystonia, Huntington's disease and myotonic dystrophy; as well as autosomal recessive conditions where the parents carry different mutations: cystic fibrosis, b-thalassaemia and congenital adrenal hyperplasia. In 2012, NIPT for thanatophoric dysplasia and achondroplasia was approved by the UK Genetic Testing Network and is now part of routine care in the UK. The translation of noninvasive prenatal diagnosis for single gene disorders into a clinical setting (NIPSIGEN) study is an ongoing project looking at other single gene disorders, such as Becker and Duchenne muscular dystrophy. 27 Of vital importance, RAPID includes parallel evaluation of the cost-effectiveness, patient acceptability, ethical, legal and social aspects of NIPT. 26 The RAPID study 26 also aims to advance practice in the area of NIPT for Down syndrome. Here, as is common to the diagnosis of aneuploidy in general, diagnosis cannot rely on the principle of paternal inheritance to distinguish the fetal from maternal genotype, which means that reliable techniques have been more elusive. NIPT for aneuploidy needs not only a high sensitivity and specificity, but also applicability to all pregnancies, irrespective of fetal gender. 28 As the most common reason why couples may be offered invasive testing is trisomy 21, its detection has been considered the 'holy grail' of prenatal diagnosis. 24, 25 Combined first trimester screening identifies approximately 3-5% of pregnancies as high risk, whereas the overall incidence of Down syndrome is only 1 in 700. 24 To try to avoid this disparity, researchers have sought to develop screening tests that have lower false-positive rates to avoid women undergoing an unnecessary invasive test that has a risk of miscarriage.
Traditional methods for detection of a trisomy involve counting the number of intact chromosomes and are unfortunately not applicable to the field of NIPT because of the cell-free nature of fetal nucleic acid. In addition, the fact that fetal nucleic acids make up a minority of the total cell-free nucleic acid in the maternal circulation means that selective enrichment or techniques that can identify the origin of the DNA molecule are needed. 28 The techniques that have been successfully implemented into clinical practice are shotgun or Sangar sequencing 29 and massive parallel sequencing (MPS). 30 Initial DNA sequencing methods could not examine the whole genome, only short strands of DNA, whereas shotgun sequencing allows analysis of sequences longer than 1000 base pairs and was therefore one of the first technologies to enable full genome sequencing. MPS is a form of high-throughput or NGS that can decode the sequences of milllions of short DNA molecules (up to hundreds of base pairs) at a time and has also been used in whole genome sequencing. 31 It is suited to prenatal diagnosis because of the small size of fetal DNA fragments. Both methods facilitate digital quantification of DNA such that it can then be counted and mapped to the chromosome of origin. 29, 30 Therefore, the relative numbers of DNA molecules from each chromosome are ascertained and, for example, the number of chromosome 21 molecules, examined to determine if the genome appears euploid or triploid, as a reflection of the status of the fetus. For NIPT to be feasible, sufficient cell-free fetal DNA must be present in the total cell-free DNA population analysed; for aneuploidy detection this is 4%. 32, 33 MPS can therefore also be utilised in twin pregnancies if the zygosity of the pregnancy can be determined and, if dizygous, the amount of cell-free fetal DNA that each twin contributes can be confirmed to be greater than 4%. 34 
Limitations
This is an exciting area of translational research, but a few limitations have been identified with more widespread use of NIPT for aneuploidy. These include indeterminate results or test failures, quoted at approximately 3%. 5 These are known to increase with rising maternal body mass index, the presence of maternal chromosomal abnormalities and in confined placental mosaicism, 19 as well as in pregnancies complicated by single twin demise. 5 This has highlighted that NIPT relies on analysis of total cell-free DNA, which includes both placental (representing fetal) and maternal components. 19 However, MPS has been shown to be able to detect 99% of fetuses with Down syndrome, for a false positive rate of less than 1%, 35 although initial detection of trisomies 13 and 18 was less successful. 36 Molecular strategies have been developed to improve the performance of MPS for all three common aneuploidies, although the detection of trisomy 13 is still somewhat poorer than trisomy 18 and 21 at 92%. 33 A 2013 study 5 reporting experience using MPS for NIPT of chromosomes 13, 18, 21 and monosomy X for a period of 6 months in 2012, has confirmed low false positive (0.2%) and false negative (0.5%) rates based on testing 5974 samples. Interestingly, the average time taken for results to be issued was 5 working days, 5 and is therefore comparable to the 3-4 working days taken to obtain results after conventional invasive testing. These figures raise the possibility that MPS testing could reduce the number of women needing invasive testing, potentially avoiding a procedure-related miscarriage. However, because of the small false positive rate for any of the common trisomies (13, 18 and 21) , those who have a high risk or failed result are still advised to undergo confirmatory invasive testing. 24 As success with NIPT for aneuploidy increases so does the drive to extend its scope to detection of non-paternally inherited single gene disorders, microdeletions such as DiGeorge syndrome (C22q11), and subchromosome rearrangements. In 2008, a PCR-based technique termed relative mutation dosage (RMD) was suggested for single gene disorders, in which the mother is often a carrier and therefore heterozygous for the mutation of interest. 37 This means that if the fetus is also heterozygous, the number of normal and mutated alleles detected from combined maternal and fetal cell-free DNA analysis would be equal; whereas if it was homozygous for either the mutated or normal allele, there would be an increased representation of mutated or normal alleles, respectively. This technique has been utilised for the detection of haemoglobinopathies 37 and haemophilia. 38 In 2010, an MPS technique, known as relative haplotype dosage (RHDO), reported the presence of the entire maternal and fetal genome through analysis of cell-free DNA in the maternal plasma. 39 This suggested that a method requiring less sequencing and lower costs could be used to explore the whole fetal genome. 39 However, with exome or genome analysis, whether from invasive or noninvasive testing, there is the potential to unearth not only clinically relevant diagnostic information but also incidental findings that have far-reaching implications for the subsequent care of not only the fetus but also the parents, siblings and wider family tree. 19 Prior to its application in prenatal diagnosis, the question of these incidental findings was a source of much controversy, and subsequently recommendations have been produced detailing what information should be reported. 40, 41 The application of genome or exome sequencing in a prenatal setting reproduces not only these concerns, but also raises the challenges of the inherent time constraints as well as the uncertainty produced where there is variation in the phenotype related to a genetic diagnosis or the available clinical data is imprecise. 19 These issues have been previously explored in relation to aCGH, where it was highlighted that both pre and post-test counselling and support, from clinical experts and nonclinical groups, are of paramount importance. 42, 43 This is particularly true if an uncertain result is obtained as this can be viewed as 'toxic knowledge'. 43 However, there is no doubt that the advances being made can provide the opportunity for more definitive genetic diagnoses for the family to utilise in decision making in the current and subsequent pregnancies.
Fetal magnetic resonance imaging (fMRI)
Another area of development in the realm of prenatal diagnosis is fMRI. This has been used for 30 years but it is only in the past decade that increasing work has been done to unlock its potential in prenatal diagnosis, namely that MRI is not limited by fetal lie, oligohydramnios, overlying bone or maternal obesity. 44 It is not suggested that MRI should replace ultrasound but instead provide an important adjunct in imaging, as MRI can offer superior soft tissue contrast resolution for a range of structural anomalies; these include thoracic, gastrointestinal, genitourinary and central nervous system (CNS) anomalies, with particular emphasis on congenital diaphragmatic hernia (where identification of the fetal liver in the thorax is useful to enable detailed counselling regarding prognosis) and oligohydramnios. 45 MRI can also be used to assist in the prenatal diagnosis of placenta accreta. 46 Most commonly, fMRI is used to assist with diagnosing CNS anomalies and the Health Technology Assessment Programme-funded Magnetic Resonance Imaging to Enhance the Diagnosis of Fetal Developmental Brain Abnormalities in Utero (MERIDIAN) study is currently assessing the diagnostic accuracy achieved with MRI compared with that achieved by the preceding detailed ultrasound examination. 47 It planned to recruit 750 women from 18 weeks of gestation onwards, and as well as looking at the diagnostic accuracy of fMRI, conditional logistic regression analysis will be performed to look at the effect of modifiers such as gestational age and the nature of the suspected brain abnormality. 47 This study was expected to report in December 2015. 47 In addition to the use of standard MRI images, there is also interest in using computer software to allow synchronous display of multiplanar MRI images that correspond to the image plane of real-time ultrasound images, known as MRI-US fusion imaging. 48 This has the advantage that the realtime and doppler capabilites of ultrasound can complement the highly contrasted MRI images to allow improved prenatal diagnosis, particularly of vascular abnormalities such as Vein of Galen aneurysms, as well as lesions traditionally poorly visualised by ultrasound, including lung masses and cerebral lesions in tuberous sclerosis. 48 This approach has been shown to be feasible in a cohort study of 25 prenatal patients and yielded useful diagnostic information, such that a larger prospective study is now needed to standardise the technique and maximise the value added. 48 An extension of the principle of computer software assisting in prenatal diagnosis is the possibility for it to play a role in planning and intraoperative guidance in fetal surgery. 49 It has been suggested that computer modelling of complex anatomy, including 3D virtual models, could assist in preoperative planning, for example visualising the vasculature of a monochorionic twin placenta in the treatment of twin-twin transfusion syndrome (TTTS). In addition, the use of realtime assisted navigation intraoperatively has been shown to be of benefit in more general endoscopic surgery, and with obvious parallels in technique to fetsoscopic surgery, offers hope that this approach could be of value in fetal therapy too. 49 Fetal therapy, and in particular fetal surgery, is a clinical reality in today's practice. Examples of this include laser treatment for TTTS, in utero transfusion for fetal anaemia ª 2016 Royal College of Obstetricians and Gynaecologists and prenatal surgery for myelomeningocele and congenital diaphragmatic hernia. Despite many positive outcomes for fetal therapy, such as in TTTS, 50 there are still examples where early cohort studies demostrated promise but subsequent randomised controlled trials or large multicentre studies indicate attenuated benefit (such as the percutaneous shunting in lower urinary tract obstruction [PLUTO] study 51 and fetal cardiac interventions). 52 As fetal interventions are likely to increase as surgical techniques and technologies improve, it highlights the vital role of robust evaluation prior to widespread implementation and the importance of the developing preoperative planning and intraoperative guidance, such as that offered with MRI, to allow any true potential to be realised.
Conclusion
In summary, it is possible the advances in prenatal diagnosis may enable us to rethink the whole structure of antenatal care, enabling a personalised and focused pathway to be developed. NIPT can provide vital clinical information and, in the case of paternally derived traits, is already successfully integrated into national health services.
MPS for aneuploidy, although available worldwide, has some limitations and is therefore considered to provide a more precise form of screening than conventional combined tests, although it cannot currently replace invasive testing for definitive diagnosis. The field of prenatal whole genome or exome sequencing offers an exciting extension of the use of MPS, and as a result is an area of considerable interest and development.
MRI imaging to complement or fuse with ultrasound offers scope to improve the diagnostic power of our current scanning. In addition, computer-assisted imaging has the potential to provide more accurate and detailed preoperative work up and intraoperative detail to continue to extend the range and success of fetal therapy procedures. However, alongside the introduction of any new technology, universal guidelines need to be developed for the data to be reported and techniques used. In addition, quality improvement and monitoring must be set up to ensure ongoing evaluation in the clinical setting; with increasing sophistication in the level of data we are able to report from prenatal investigations comes increasing responsibilty to ensure that the information we provide is assisting families and that we are providing this information for clinically indicated reasons.
Further fascinating work is already underway to perform chromosome therapy and facilitate inactivation of the extra chromosome 21 in Down syndrome. Needless to say, this is not the last you will hear on the developments in the prenatal field, as great advances have been made in the past few decades and these look poised to continue.
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